A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
<p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | BMC Infectious Diseases |
Online Access: | http://www.biomedcentral.com/1471-2334/8/100 |
id |
doaj-03edfaafed334dfd9b73811b3928d991 |
---|---|
record_format |
Article |
spelling |
doaj-03edfaafed334dfd9b73811b3928d9912020-11-25T03:40:11ZengBMCBMC Infectious Diseases1471-23342008-07-018110010.1186/1471-2334-8-100A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccinesChionne PaolaRapicetta MariaOddone MaurizioZito SalvatoreMarchisio MariaMontù DomenicoBarale AntonellaBella AntoninoGiambi CristinaMadonna ElisabettaAtti Marta<p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac<sup>® </sup>was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.</p> <p>Methods</p> <p>Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.</p> <p>Results</p> <p>Sera from 113 children previously vaccinated with Hexavac<sup>®</sup>, and from 124 vaccinated with Infanrix Hexa<sup>® </sup>were tested for anti-HBs. Titers were ≥ 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers ≥ 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).</p> <p>Post-booster, 93% of children achieved titers ≥ 10 mIU/ml, with no significant difference by vaccine group.</p> <p>Discussion</p> <p>Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time.</p> http://www.biomedcentral.com/1471-2334/8/100 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chionne Paola Rapicetta Maria Oddone Maurizio Zito Salvatore Marchisio Maria Montù Domenico Barale Antonella Bella Antonino Giambi Cristina Madonna Elisabetta Atti Marta |
spellingShingle |
Chionne Paola Rapicetta Maria Oddone Maurizio Zito Salvatore Marchisio Maria Montù Domenico Barale Antonella Bella Antonino Giambi Cristina Madonna Elisabetta Atti Marta A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines BMC Infectious Diseases |
author_facet |
Chionne Paola Rapicetta Maria Oddone Maurizio Zito Salvatore Marchisio Maria Montù Domenico Barale Antonella Bella Antonino Giambi Cristina Madonna Elisabetta Atti Marta |
author_sort |
Chionne Paola |
title |
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
title_short |
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
title_full |
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
title_fullStr |
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
title_full_unstemmed |
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
title_sort |
cohort study to evaluate persistence of hepatitis b immunogenicity after administration of hexavalent vaccines |
publisher |
BMC |
series |
BMC Infectious Diseases |
issn |
1471-2334 |
publishDate |
2008-07-01 |
description |
<p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac<sup>® </sup>was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.</p> <p>Methods</p> <p>Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.</p> <p>Results</p> <p>Sera from 113 children previously vaccinated with Hexavac<sup>®</sup>, and from 124 vaccinated with Infanrix Hexa<sup>® </sup>were tested for anti-HBs. Titers were ≥ 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers ≥ 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).</p> <p>Post-booster, 93% of children achieved titers ≥ 10 mIU/ml, with no significant difference by vaccine group.</p> <p>Discussion</p> <p>Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time.</p> |
url |
http://www.biomedcentral.com/1471-2334/8/100 |
work_keys_str_mv |
AT chionnepaola acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT rapicettamaria acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT oddonemaurizio acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT zitosalvatore acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT marchisiomaria acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT montudomenico acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT baraleantonella acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT bellaantonino acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT giambicristina acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT madonnaelisabetta acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT attimarta acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT chionnepaola cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT rapicettamaria cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT oddonemaurizio cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT zitosalvatore cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT marchisiomaria cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT montudomenico cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT baraleantonella cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT bellaantonino cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT giambicristina cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT madonnaelisabetta cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines AT attimarta cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines |
_version_ |
1724535687089225728 |